![]() | |
Clinical data | |
---|---|
Trade names | Trocoxil |
AHFS/Drugs.com | International Drug Names |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.248.948 |
Chemical and physical data | |
Formula | C16H11F4N3O2S |
Molar mass | 385.34 g·mol−1 |
3D model (JSmol) | |
| |
|
Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[2] It acts as a COX-2 inhibitor.[3]
Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[4][5]
((cite journal))
: CS1 maint: overridden setting (link)
((cite news))
: CS1 maint: overridden setting (link)
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams |
|
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |